Stoke Therapeutics, Inc.
STOK
Price:
$31.05
Market Cap:
$1.77B
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery...[Read more]
Industry
Biotechnology
IPO Date
2019-06-19
Stock Exchange
NASDAQ
Ticker
STOK
PE Ratio
[45.66]
ROE
[13.28%]
Current Ratio
[6.53]
Dividend Yield
[0%]
Enterprise Value
[1.69B]
Dividend History
The ROE as of December 2025 (TTM) for Stoke Therapeutics, Inc. (STOK) is 13.28%
According to Stoke Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 13.28%. This represents a change of 546.86% compared to the average of 2.05% of the last 4 quarters.
Stoke Therapeutics, Inc. (STOK) Historical ROE (quarterly & annually)
How has STOK ROE performed in the past?
The mean historical ROE of Stoke Therapeutics, Inc. over the last ten years is 23.38%. The current 13.28% ROE has changed -43.22% with respect to the historical average. Over the past ten years (40 quarters), STOK's ROE was at its highest in in the March 2018 quarter at 147.99%. The ROE was at its lowest in in the March 2024 quarter at -18.79%.
Average
23.38%
Median
-28.56%
Minimum
-65.62%
Maximum
430.19%
Stoke Therapeutics, Inc. (STOK) ROE by Quarter and Year
Discovering the peaks and valleys of Stoke Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.75%
Maximum Annual ROE = 430.19%
Minimum Annual Increase = -102.77%
Minimum Annual ROE = -65.62%
| Year | ROE | Change |
|---|---|---|
| 2024 | -38.85% | -40.79% |
| 2023 | -65.62% | 20.01% |
| 2022 | -54.68% | 38.77% |
| 2021 | -39.40% | 115.75% |
| 2020 | -18.26% | 26.79% |
| 2019 | -14.40% | 20.86% |
| 2018 | -11.92% | -102.77% |
Stoke Therapeutics, Inc. (STOK) Average ROE
How has STOK ROE performed in the past?
The current ROE of Stoke Therapeutics, Inc. (STOK) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-53.05%
5-year avg
-43.36%
10-year avg
23.38%
Stoke Therapeutics, Inc. (STOK) ROE vs. Peers
How is STOK’s ROE compared to its peers?
Stoke Therapeutics, Inc.’s ROE is greater than Intellia Therapeutics, Inc. (-57.24%), greater than Upstream Bio, Inc. (-35.90%), greater than Ardelyx, Inc. (-36.91%), greater than Spyre Therapeutics, Inc. (-31.18%), greater than Wave Life Sciences Ltd. (-72.94%), greater than Zymeworks Inc. (-24.48%), greater than Pharvaris N.V. (-69.10%), greater than Novavax, Inc. (-167.00%), less than BioCryst Pharmaceuticals, Inc. (1.93%), greater than Zenas BioPharma, Inc. (-59.19%),
| Company | ROE | Market cap |
|---|---|---|
| -57.24% | $1.02B | |
| -35.90% | $1.50B | |
| -36.91% | $1.42B | |
| -31.18% | $2.02B | |
| -72.94% | $1.25B | |
| -24.48% | $1.99B | |
| -69.10% | $1.80B | |
| -167.00% | $1.11B | |
| 1.93% | $1.65B | |
| -59.19% | $1.60B |
Build a custom stock screener for Stoke Therapeutics, Inc. (STOK) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Stoke Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Stoke Therapeutics, Inc. (STOK) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Stoke Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Stoke Therapeutics, Inc.'s ROE?
How is the ROE calculated for Stoke Therapeutics, Inc. (STOK)?
What is the highest ROE for Stoke Therapeutics, Inc. (STOK)?
What is the 3-year average ROE for Stoke Therapeutics, Inc. (STOK)?
What is the 5-year average ROE for Stoke Therapeutics, Inc. (STOK)?
How does the current ROE for Stoke Therapeutics, Inc. (STOK) compare to its historical average?